Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib

Isabel M. Haugh, Ian T. Watson, M. Alan Menter

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.

Original languageEnglish (US)
Pages (from-to)524-525
Number of pages2
JournalBaylor University Medical Center Proceedings
Issue number4
StatePublished - Oct 2 2018
Externally publishedYes


  • Atopic dermatitis
  • JAK1
  • eczema
  • oclacitinib

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib'. Together they form a unique fingerprint.

Cite this